Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for this: I can't access Seeking Alpha Pro, so can't read the link. Still trying to understand, though, why the KDUS chart is on the Phillip Frost iHub site and nothing else references his ownership of shares. I'll re-read the other stuff, maybe I'm missing something.
Very helpful thoughts Steve. You display a solid grasp of Frost-related investing and I appreciate it.
Kind regards,
Minding
Someone over on the COCP board had noted to me how a COCP drug was now being developed by BLRX. While BLRX is not per se a Frost company, BLRX was a creation largely of TEVA during Frost's tenure. BLRX has proven to be an honest broker, developing and testing compounds and devices for other companies, in this case for COCP/RFS. It can lead to significant revenue downstream for COCP. I would also speculate (pure speculation, no written evidence) some interest in Frost acquiring BLRX and merging it into his OPK conglomerate long-term.
I see this as all part of Frost having his different companies work together. It foreshadows either transfer/licensing of the drug/device/process (speaking generically here, depending on the company) or acquisition.
I am sitting patiently waiting. I tried to be careful which of Frost's entities I invested in, because they are not all of the same quality and/or stage of development. He has a long-term game plan and I can wait for developments. I have no reason to deride anyone who chooses to invest in all of Frost's companies or different ones than those in which I invest. It's all a matter of taste and investing approach.
I know Icahn's an owner, but this board seems to display KDUS as one of Frost's stocks - aren't the charts shown here of stocks he owns?
That's because he doesn't,
were you thinking of Icahn mayhaps?
I can't find any records of Dr Frost owning KDUS. Not in the SEC filings or the major owners listed on the finance.yahoo site. Can anyone point to a reference on this?
Personally I don't think it is Frost yet. They will obviously be raising other monies as they grow. This was a great financing without diluting shareholders. They raise the monies needed to grow and get their new platform IDI CORE out which is superior to the competitions and then drive revenues. Going to be a fun ride.
Looks like Frost may have stepped in to stabilize.
Is that how you see it? Wonder if personal stake, one of his companies or investment arm.
Thanks for posting the news.
IDI up 13.3% on $10M direct offering
Jul 24 2015, 10:29 ET | By: Jason Aycock, SA News Editor Contact this editor with comments or a news tip
IDI is up 13.3% after announcing a $10M direct offering to an institutional investor, along with a concurrent private placement of warrants.The company agreed to sell just over 1.28M shares at $7.81/share, along with warrants to purchase 0.5 share for each of those common shares at $10/share. The warrants are exercisable six months from issue and expire 36 months after issue.“We believe this financing serves to significantly accelerate the long-term development of the company,” says co-CEO Derek Dubner.Shares plummeted 48% on Tuesday after a Pump Stopper article said it had a 92% downside and was at risk of "total wipeout." Shares have regained 55.4% since then, but are still down 23.5% over the past five days.
Insiders making big purchases is certainly a highly visible way to state undervalued.
Nice move for those with guts to buy blood. Nice recovery for those with guts to hold.
The fear driven sellers got crushed.
Thanks for the post.
$IDI Insiders buying ... HUGE BOUNCE BACK FROM $5.17!!!!! WEEEEEEEEEEEE!!!1
Form 4.
https://searchwww.sec.gov/EDGARFSClient/jsp/EDGAR_MainAccess.jsp?search_text=Idi&isAdv=false
Mille Grazie!
Edit: I recall similar attacks on Frost and OPK either late in 2013 or early in 2014. Clearly coordinated short attack, selling short first.
Thanks SC. I will look a little deeper.
I caught pieces of two runs in GALE previously. It is on my list and keeps trying to entice me again, but don't quite get all signals lined up. Looks to either test lower again or go sideways ST.
http://stockcharts.com/h-sc/ui?s=GALE&p=D&yr=0&mn=2&dy=0&id=p12754752509
TRXC looks interesting but know nothing about it yet.
http://stockcharts.com/h-sc/ui?s=TRXC&p=W&b=5&g=0&id=p49848018177
COCP trying to line up, but not quite there yet. Again, chart only. Need the dd.
http://stockcharts.com/h-sc/ui?s=COCP&p=D&yr=0&mn=2&dy=0&id=p94181649586
Not sure about R/S impact or if news to offset.
OPK looks great. Congrats
http://stockcharts.com/h-sc/ui?s=OPK&p=W&yr=2&mn=0&dy=0&id=p94045377980
Here's a little look from the 1 yr view with possible support/resistance and price targets.
Great that you have gains to mitigate risk.
Be Green
Cit, Some further thoughts:
1. I also have some ROX which I think will do well. In at 86 cents average, so the current movement doesn't bother me. Some very good posters there. I know you know how to tell the difference.
2. Have a tiny and recent position in DRNE, where Funman had done and posted a lot of DD. Interesting prospects for tethered drones, a very much more professional approach than free-flying ones. I also like the coup Frost staged to install new management and incent them with benefits they can't reach by just showing up.
3. I'm not a chartist, tho I can read stuff like BBs. Primarily a logical DD guy.
Cit, I agree the secular trend in precious metals has worked against PGLC, but I feel, as do you, that they are doing the right things to prove out the reserves. Really smart not having launched into production, altho it may be a while until a major is interested in acquiring and Barry Honing's shares do give me a bit of pause. I had passed up the recent opportunity to participate in the PIPE, as I did not intend to invest more here. Management thus far has resisted giving me estimates of silver and other PMs on the property; suspect they only tested quantitatively for gold.
Ultimately, I'd like your opinion on ATNM.
We are indeed in several other stocks together.
Great synopsis. Thanks
I agree that there are individual stocks worth investing in. Probably would not trade them all.
As a chart player as well as a long the chart has to be in my favor.
I have traded PGLC a couple times and watched it for 3 years. The long down trend in metals has pressured it just like the other exploration/growing miners. The property speaks for itself IMO and it has progressed nicely in preparing for processing, permitting etc.
SVON is interesting, however the lack of volume/liquidity is an issue right now.
ATNM I am watching closely.
I have several on a watch list and will evaluate if/when they give a buy signal.
Be Green, we seem to like many of the same stocks.
I should add, I am a fan of SYN and doing well.
Cit, Interesting piece which seems to have attracted many of the Frost haters of the world. Certainly lots who bear a grudge against Brauser and Honig. Interestingly, Frost's main vehicle, OPK, did well today.
When I was first beginning to track Dr Frost, I looked at many of the companies cited here, did my DD and decided I was not interested. I did invest in PGLC, which was mentioned and am down about 27%. Up over 230% in OPK, as of today. Way overweight in OPK. Up over 75% in COCP, but the comparative lack of transparency, since I bought some BZNE shares, gave me a lot of gas. Ity bitty investment there.
Certainly the article has allegations which should be processed by longs when they do their period reassessment. Not something for a kneejerk reaction, as it has many hallmarks of a classic hatchet job.
2 posts before this post
I cautioned people to do a little work before investintg their money in Frost plays, to learn their M.O.s and nuances at the very least. Not many want to hear it or find that it doesn't fit well into plans.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115411271
One Ihub poster 'coastiretred' has written quite a bit on Honig, Brauser and Frost and Ihub's own 'nodummy', the most awesome fraud investigator on the planet imo, has some things to say about a few Honig and Brauser plays. Other than that there is other info available on the net including a 2013 SA article, but none directly implicating Frost or Frost actively participating in fraud.
Any comments on this seekingalpha article. Took the wind right out of IDI.
http://seekingalpha.com/article/3342225-idi-strong-sell-on-fraud-lawsuits-bankruptcy-and-technology-failure-minus-92_4-percent-downside
Knowingly or unknowingly seems he is hooked up with these guys.
Don't his investment people do better dd?
I'm guessing he has some good ones, but how to ferret them out is the key.
How many articles will be put out and on what companies.
SVON has looked pretty good but very thinly traded as are many others.
Based on where he started Frost would seem above this sort of thing.
What is the truth?
Just trying to figure if these are chart only plays or is there is some substance.
PGLC seems real based on amount of capital expended and infrastructure buildout, permits etc.
Thanks for comments from those who follow Frost closely.
PKTX Dr. James Shapiro one of the leading transplant surgeons and experts in the world on diabetes has spoken about the AAGP molecule and the success it has shown.Very interesting
Keep in mind, money to be made
and lost in Frost plays, I've done both. Learn what the hell you are doing,how and when it works, there will be R/S's, offerings,
promotions (3rd. party & co.) and the possibility of Barry Honig and/or Michael Brauser skulking around in the background.
Do some work.
He needs to get some PKTX before it takes off.
I think this guy just loaded up big on $ATNM. http://www.bizjournals.com/southflorida/news/2015/06/05/miami-beach-billionaire-frost-leads-investment-in.html#i1
LVNVF, CLS Therapeutics just acquired 19.5% of the company on 7-9-15
http://www.thestreet.com/story/13215300/1/cls-therapeutics-limited-acquires-shares-of-scivac-therapeutics-inc.html
$SRNE - Besides Frost, the other big name everybody chases in Dr. Patrick Soon-Shiong. He owns 20% of SRNE and is CEO and major shareholder of pending IPO Conkwest ----which has a large JV with SRNE.
Patrick Soon-Shiong is RICHEST DR. in the WORLD
-------------------------------------------
SRNE will be huge derivative play on coming Conkwest IPO.
CAR-TNK S-Ss-s) and Biotech whiz is CEO of ConkWest and owns large amount of stock.
Dr. S-S also owns 20% of SRNE and SRNE has deals with Dr. S-S' $7 billion dollar Nantworks.
MOST OF ALL, SRNE owns a chunk of Conkwest and has joint venture with them developing the NK pipeline.
Also SRNE is going to do their own Spin-out of their CAR-TNK operation in 2015 or 2016.
Conkwest IPO will price with a market cap of close to $2 billion.
Can anybody comment on VPCO and Frost's current involvement and intentions?
SVON could be Dr.Frost biggest investment return.,solid developments. Well known management,Pfizer,Dr. Frost ,great SS ,low cap, solid balance sheet,enough cash(Raised almost $5m Since May 1),a joke market cap($15m) trial Phase and a well known billionaire that took a solid position here. A matter of time imo
when it goes, it will go hard and fast. $3+ imo
DD for new investors:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115082713
LVNVF looking to test .50, Frost merger with SciVac set to close tomorrow.
$IDI - IDI, Inc. Announces Its Inclusion in the Russell Microcap Index(R)
7:30 AM ET 6/23/15 | BusinessWire
IDI, Inc. (NYSE MKT: IDI), an information solutions provider and multi-platform media company, today announced that it has been added to the Russell Microcap Index(R) following the conclusion of the Russell indexes annual reconstitution on June 26, 2015, according to the update of the preliminary list of reconstitution additions and deletions posted on June 19, 2015.
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell, a leading global index provider, determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
"We are extremely pleased to join the Russell Microcap Index(R) as it strongly coincides with our increased efforts to broaden our shareholder base and share our redefined growth strategy with the investment community," stated Mr. Derek Dubner, Co-CEO of IDI, Inc. "We look forward to building upon our new position within the data fusion space and sharing our progress with now a greater investor audience as we move forward."
About IDI, Inc.
IDI, Inc. is an information solutions provider focused on the multi-billion dollar data-fusion market. IDI delivers otherwise unattainable insight into the ever-expanding universe of consumer- and business-centric data. Through proprietary linking technology, advanced systems architecture, and a massive data repository, IDI will address the rapidly growing need for actionable intelligence to support the entirety of the risk management industry, for purposes including due diligence, risk assessment, fraud detection and prevention, authentication and verification, and more. Additionally, IDI's cross-functional core systems and processes are designed to deliver an unrivaled level of clarity into consumer data to support advanced marketing analytics. IDI also operates a multi-platform media company operating in China, which provides advertising services in the out-of-home advertising industry, including iScreen Outdoor LCD screens and billboards.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipate," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward looking statements include statements about whether joining the Russell Microcap Index(R) will coincide with our efforts to broaden our shareholder base and growth strategy with the investment community. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risks set forth in IDI's Annual Report on 10-K, filed with the SEC on April 15, 2015, as well as the other factors described in the filings that IDI makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150623005516r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623005516/en/
SOURCE: IDI, Inc.
For IDI, Inc.
MDM Worldwide Solutions
David Zazoff, 646-403-3554
recap of Dr Frost's OPK purchases including yesterday's 9000 shares
http://openinsider.com/search?q=opk
Yes I follow that as well
From Fridays action...you may want to look at ATNM. Something is stirring up interest.
I think Philip Frosts most undervalued play or should I say play with the greatest price appreciation potential is IDI. My opinion
I was just thinking the same thing. From the looks of it, there's a good possibility he's taken quite a beating in some of these. For example: TRXC, in which Dr. Frost had a large position, was doing nicely about a year ago, then reverse split and became valued about $10. So far, so good, uplisting potential, but it then almost immediately did an offering at $4, giving everyone, including me -and him- a 60% haircut. Also, is he invested in special classes of any of these stocks that aren't available to the rest of us? He's supposedly a great investor, but that's not necessarily apparent with the information we see here.
would be nice if this board had a record of frost stocks with entry prices to show performance ...either a sticky or in the intro message
no wise crack replies please
Discussion and evaluation of OPK.
Most people know the medications that we are working on, which is good, but there isn't much in depth information on them easily available. I researched the drugs and include a write up on them so that people could decide for themselves if the drugs that we are developing are breakthrough drugs, or just copies of old drugs, and therefore not really worth anything. Plus I include an evaluation on OPK.
Our prostate 4Kscore test has already been approved and OPK is contacting urologists and explaining that its use will greatly decrease the number of prostate biopsies that have to be performed. The test is being accepted by more and more urologists here in America, Europe and now Mexico. In fact, in just the last quarter, the number of urologists that said that they were going to use the test, increased by 50%.
Every procedure done by a doctor has a CPT (Current Procedural Terminology) code number assigned to the procedure, and it is that number that is sent to the insurance company and Medicare for payment. Without that code, the patient has to pay for the test themselves, and so actual use of the test has been low. We have finally been issued our CPT code, and now use of our 4Kscore test should dramatically increase. According to what I have found in researching the 4Kscore test, the yearly income should eventually be 2 billion dollars, and then climbing, because the number of men being diagnosed with prostate cancer is growing yearly.
We are in the final stages of getting approval for Rayaldee, the first and only modified slow release formula of calcifediol, a major transport form of vitamin D, for end stage renal disease patients. In patients with end stage renal disease, when they take vitamin D, the body produces an abnormal enzyme CYP24, which destroys it. Even taking very high doses of vitamin D will not overcome this destructive process. This causes patients with kidney disease to have extremely low levels of vitamin D which causes the bones to lose calcium into the blood stream. The calcium is then deposited into the soft tissues, such as the veins, and causes severe cardiovascular disease and other problems. Rayaldee is a first in class slow released vitamin D drug and the Phase I and II tests have shown that it does not cause the release of CYP24, and in addition to that, it raised the vitamin D levels to normal levels.
Dr. John Cannell, an acknowledged expert on calcifediol, was so impressed with our Rayaldee drug that on 6 January 2014 he wrote that he had invested his life savings in OPK. OPK stock at that time was in the $8 to $9 range, so even at $15 a share he is in good shape.
Opko Health, in its press release, said that sales of Rayaldee should reach $6 billion a year. This may sound like a lot, but analyst reports that I have read, put the amount at $12 billion to $24 billion dollars a year if it is used world wide and $6 billion just for the U.S. market. And since the company plans on selling it in Europe, Mexico + Central America, and Asia, I would think that sales of $6 billion a year is conservative. In fact, OPK, in its official SEC Form 8K filing, lists it as worth $12 billion a year.
OPK owns global rights to a heparin-derived oligosaccharide intended for therapeutic use in asthma and COPD (chronic obstructive pulmonary disease) as well as cystic fibrosis and other respiratory diseases. It is more efficient than current asthma medications and doesn't have their side effects.
Initial studies, using animals, have demonstrated successful anti-inflammatory and anti-allergic activity when administered orally or inhaled with inhalers or nebulizers. Human feasibility studies for asthma have also proven successful.
OPK also has an advanced inhaler which is superior to present inhalers and easier to use.
Inspiromatic™ offers improved drug deposition to the lower airways of patients and real time data for patient compliance monitoring. The device has an internal microcontroller and flow sensor that controls the delivery of the medication and, using micro-pump technology, dispenses the drug particles at the right speed without the need for forceful inhalation. It also provides instant feedback to the patient with a green or red flasher light to indicate proper inhalation and a beeper after the dose has been delivered. For physicians, Inspiromatic™ provides a built-in logger that stores patient use data for easy access and transmission by electronic devices such as smart phones.
In a recently completed, First In Man double blind clinical study, conducted with 30 asthmatic children, comparing Inspiromatic™ to a market leading inhaler, it demonstrated superior pulmonary delivery of the active drug.
The present drug of choice is Advair, which also uses an inhaler. Its annual sales are +$2 billion a year. OPK's drug is more effective and has less side effects, plus its inhaler is much more effective, so it will probably win over much of the market and should end up with yearly sales in the range of $2 billion.
OPK’s Factor VIIa hemophilia drug is unlike any of the hemophilia drugs now in use. It has received an orphan drug designation, so that means it will be fast tracked to approval. All the hemophilia drugs in use today have to be given by IV and are short acting, only staying active in the body for about a day. Bayer, and two other companies, are developing a longer acting drug that only has to be given once a week, but those drugs also have to be given by Intravenous Injection. This is especially difficult for infants and children because they have such tiny veins, but it is also awkward and painful for adults. Either a needle has to be inserted into their vein, which is painful and causes scaring of the vein, which over time makes the vein unusable, or a port has to be inserted, and long term IV ports have a risk factor of becoming infected.
OPK has developed a long acting drug, which also only has to be given once a week, but it is given subcutaneously. Subcutaneously means under the skin. The medicine is drawn up into a syringe and then injected under the skin using a tiny needle. You don't use a long or big needle because the medication is given into the layer of fat under the skin. The fatty tissue is filled with tiny capillaries which slowly absorb the medication. A larger needle, like the ones given for shots in the buns, ouch, are not used. You don't want the needle to go through the layer of fat and into the muscle, because the muscle is filled with blood vessels, plus there is a lot of movement of the muscle, and so the medicine would be absorbed much faster and so last a shorter time.
People can do the procedure by them selves at home. Or parents can do it for their children. The drug can be used for emergency episodes, such as a cut, but its main use would be self-administration at home for prophylactic use to prevent bleeding episodes. Hemophiliacs can spontaneously start bleeding for no apparent reason, typically into the joints and muscles, and that can cause permanent damage over time. Therefore it would be best to be given on a regular (weekly) basis for life. That is why it would bring in so much money for our company, because it will be given for life and not just for occasional emergency uses. Since our medication is given subcutaneously, instead of by IV, it would be the drug of choice. OPK states it would be worth $3.5 billion a year.
OPK, working with The Scripps Research Institute, is developing the only Parkinson drug that can actually stop the progression of the disease, instead of just delay it. SR 3306, a novel compound discovered by scientists at The Scripps Research Institute, stops the death of the brains cells whose destruction leads to Parkinson's disease. In the mid brain area is a group of dark colored cells, called substantia nigra, which produce a compound called dopamine. The dopamine is transported along the axons of the nigra cells to the stratium cells that control the movement of the muscles.
In Parkinson's disease, the substantia nigra cells die off and as the stratuin muscle controlling cells receive less dopamine, a person loses control of his muscles. Dopamine will not cross the blood brain barrier, bit it turns out that levodopa, a compound produced by certain plants, will travel through the blood stream, cross the blood brain barrier, and enter the brain. Once levodopa has entered the central nervous system, it is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase. Levodopa's effect on Parkinson's disease isn't a new discovery, over 7,000 years ago, in 5,000 BC, there are recordings of people with symptoms identical to Parkinson's and they were treated with the plants that contain levodopa. The extra dopamine that is produced by the levodopa, along with the output of dopamine from the remaining nigra cells, gives a person back normal control of their muscles. The problem is, that the nigra cells continue to die off, and increasing the levodopa to compensate for their loss can't be done because large amounts of levodopa are toxic. Because the nigra cells continue to die off, eventually their production of dopamine isn't enough to maintain muscle control and the person starts a downward spiral to death.
OPK's SR 3306 compound inhibits a class of enzymes called jun-N-terminal kinases (JNK) that are involved in the death of substantia nigra cells in persons with Parkinson's disease.
JNK is involved in apoptosis (self induced cell death) and survival signaling of cells and was identified in the death of neuronal cells. Since people with Parkinson's already have decreased nigra cells, and so don't produce enough dopamine, they will still need to continue taking their levodopa, but they will also be given SR 3306, which will stop the destruction of their remaining nigra cells, and so it will stop the actual progression of the persons Parkinson's disease. This is a life changing event. Something that no other drug can do, and in situations where there is no known drug to stop a disease, the FDA has a special fast tract procedure that they use. Our drug fits in this category.
There are over a million people with Parkinson's disease in America and another 9 million worldwide. The market for our Parkinson's drug would be over a billion dollars a year.
Here is a drug that could be interesting. OPK is working on a new vaccine design that could be applied to vaccines for regular influenza, plus the many strains of influenza such as ‘swine flu’, ‘bird flu’, and perhaps other viral diseases such as Hepatitis C and HIV.
Hemagglutinin is the key molecule that determines the entry of a virus into a host cell. Experiments were done to see how the hemagglutinin protein found on the surface of influenza viruses binds to the host cell, including how glycans (sugar chains) attached to the surface of hemagglutinin affect the binding. The surprising discovery was made that hemagglutinin stripped of most of its glycans bound more strongly to host molecules than fully glycosylated hemagglutinin. Vaccines were constructed and tested on mice. The investigators found that the ‘nearly naked’ mono-glycosylated hemagglutinins were able to neutralize a broader spectrum of virus types than the regular fully glycosylated hemagglutinins. They also found that mice given a vaccine made from hemagglutinins with less glycan attached to the surface and then given a lethal dose of influenza virus, increased survival rate by up to 50% in comparison with unvaccinated animals.
Up until now, only regular fully glycosylated hemagglutinins have been used in the production of vaccines. The mono-glycosylated hemagglutinin as a vaccine in this study showed a stronger immune response with broader neutralizing activities against H5N1 and H1N1 influenza. The team leader of the investigators in the mouse study, Dr. Chi-Huey Wong, said,”Glycan modeling could pave the way to the development of a universal vaccine against influenza and other human viruses.“ A universal virus vaccine would be a game changer.
Opko Health has been trying to develop a vaccine using this technique for five years, but so far has not come up with a vaccine that meets the criteria for a phase I test. If we ever come up with a vaccine that works, that could be a real money maker.
All the reports that I have read say that our calcifediol end stage kidney disease medication will be our biggest winner at $12 billion a year, while they only mention in passing the drug that I think could actually be our biggest money maker, literally worth tens of billions of dollars a year. In Opko Healths Form 8K filing it stated that the drug would bring in over 15 billion dollars a year. That drug is our weight reducing candidate, and what is interesting, is that it also directly lowers blood sugar levels and cholesterol levels.
Because obesity isn’t a disease, regulators have a low tolerance for worrisome side effects. On the other hand people that are morbidly over weight (and are designated as obese, not just overweight) develop many medical problems, such as diabetes, and die young. Weight loss counseling and the weight loss medications available today do not work on these people. 400,000 people in America die from obesity related problems every year. So far the only treatment available is a gastric bypass surgery called Roux-en-Y, which itself can cause life threatening complications. So if a medication was developed that induced weight loss in this group of people, and thus obviated the need for surgery, the FDA would consider expediting its approval, especially considering the death toll from obesity related problems.
Drug companies have spent decades and over a billion dollars trying to come up with a weight loss drug. Older weight loss medicines made by companies like Sanofi and GlaxoSmithKline Plc stumbled because they were deemed too dangerous or came with unpleasant side effects. In the last few years four new drugs have been approved by the FDA, but so far their sales have been weak.
OPK, along with Prolor Biotech, are working on oxyntomodulin, a peptide hormone produced by cells in the small intestine where It is released into the bloodstream when a person ingests food, and travels to the brain, where it acts to enhance satiety and reduce appetite. Since it is a natural compound produced by the body, previous tests showed that it did not have any side effects. Previous companies have tested it, and it did induce weight loss, but it is short acting and had to be injected subcutaneously multiple times a day, usually just before meals. Which was awkward. How would you like to inject yourself just before you eat at a restaurant? Or even before meals at home or at work.
Other companies tried to make a long acting form of oxyntomodulin, but all the forms that they came up with had only weak weight loss effects. When they changed the structure of the oxyntomodulin molecule, it lost its effectiveness. However, Dr. Frost is famous for either taking previous medications that were ineffective and redesigning them to greatly enhance their properties, or finding and buying companies that had come up with a redesigned medication. He has done it again with oxyntomodulin.
Prolor Biotech, using Reversible PEGylaton technology, which leaves a compound intact, but adds a molecular tail to it to change its characteristics, has developed a long acting oxyntomodulin (dual GLP-1/Glucagon agonist) called MOD-6030. It is a slow release form of the intact oxyntomodulin, enabling a prolonged exposure of the peptide while maintaining its biological activity and the ability of the peptide to pass the blood brain barrier. Tests showed that it only has to be given once a week. Unexpectedly, not only did the drug not lose any of its effectiveness, it had a much stronger weight loss effect than the natural hormone oxytomodulin itself, and it even improved glycemic control, lowering blood sugar levels, thus meaning it could also be used as a diabetic drug, plus it had a large cholesterol lowering effect. It should be noted that diabetics also have problems with elevated cholesterol. It turns out, that since it stays active in the body for days at a time instead of just a few hours, its effects are strongly enhanced and factors that weren't previously apparent, such as its diabetic and cholesterol properties, show up.
In a 30 day animal study, animals in the placebo group, which received normal saline injections, showed minimal changes in the study parameters, while the animals receiving MOD-6030 achieved on average a 28% reduction in weight, a 29% reduction in food intake, a 19% reduction in blood glucose levels and a 57% reduction in cholesterol levels. The lead investigator stated, “We believe there is great demand among obese patients and their physicians for therapies that will help patients lose weight and reduce elevated glucose levels." I would add that diabetic doctors would also be interested in the drug, either as a stand alone drug, or for it to be given along with a patients' diabetic drugs. And since diabetic drugs have side effects, some of them serious, adding our drug to their protocol may enable them to lower the dosage of their diabetic drug, thereby decreasing their risk of side effects.
As of January 2015, over 2 billion adults, 18 years or older worldwide, were overweight, and of those, over 600 million were obese. In America over 70 million adults are obese. Because of this, OPK states that its weight loss medication could bring in $15 billion a year. Other analysts put the number even higher. What none of them mentioned was that there are over 400 million diabetics world wide, with 70 million being in America. I would think that a number of those could end up taking our drug, so we could end up making well over 15 billion dollars a year if our weight loss drug works. Even if we only end up with a lower percentage of that, it would still be a very lucrative drug.
We are working on a slow release human growth hormone (hGH), another ground breaking development, since all other hGH drugs are short acting. hGH is given to children 2 years and older that have not reached the minimum normal height range. And increasingly, doctors are also prescribing it for adults. It increases muscle mass in the elderly. It also increases muscle mass in cancer and AIDS patients that have developed cachexia, a condition where the body breaks down muscle mass. In addition to that, hGH increases heart function, stamina, sexual ability in men and reverses vaginal dryness and fragile/thin vaginal skin in older women. It also enhances the immune system. Because of these reasons, and many more, it is being increasingly prescribed for adults. And as the population ages, hGH sales will be in a strong uptrend.
Even though hGH has many properties that would make people want to take it, and make doctors want to prescribe it, many people decide against using it because it has to be taken daily, plus daily injections are expensive. OPK has developed a long acting hGH that only has to be injected once a week. It is in phase III in adults and phase II in children. The present yearly market for hGH drugs is 3 billion dollars a year. Since our drug only needs to be given once a week, instead of daily, it will be the drug of choice. Plus more people will decide to take it since it only needs to be taken once a week, and more people will choose to take it because it will also be less expensive since it is not taken every day.
But even though this was a drug that would be an excellent cash cow if the drug trials could be advanced all the way through FDA approval, we didn't have enough money to finish running the tests on hGH, plus all our other drugs. Dr. Fisher talked to Pfizer, and they came to the rescue. They gave us $295 million up front, which brought us to a cash balance of $348 million, plus they agreed to pay another $275 million dollars to fund both our child and adult studies through to FDA approval. This means that we will end up getting a total of $570 million, over half a billion dollars, and when added to our own cash balance of $53 million it gives a total of $623 million. And once Pfizer starts selling the drug we will get royalty payments.
According to a paper on drug royalties, written by Goldscheider, since a company that develops a drug shoulders most of the expenses, they get a large royalty. And if it is a drug that will not face competition, and thus will be able to be sold for good profits, such as our drug, they will get even larger royalties. The company that acquires the rights to the drug and then starts selling the drug, after expenses, will usually have a profit of 50%. Per Goldscheider, royalties will be 25% of the profit for drugs not facing completion. That would work out to a 12.5% royalty and on revenues of $3 billion yearly, that would mean that OPK would get $375 million a year.
So, not only will we get over half a billion dollars, enough to fund all our drug studies through to FDA approval, we will also receive $375 million a year from royalties. Prior to our deal with Pfizer, our company was in difficulty because of its high cash burn and commentators were saying that OPK might cease to exist. Most companies would not know what to do, but Dr. Fisher turned a liability into an asset. It is this ability of Dr. Fisher, to see solutions where other people only see disaster, that makes our company so great.
Dr. Fisher is always looking for ways to help the company, and he comes up with solutions that no one else would see. In 2009, Schering-Plough, a large pharmacological company, was working on the drug rolapitant for nausea and vomiting caused by chemotherapy. They hoped that it would be better than present drugs and longer acting, but their phase II trial didn't show that it was effective for either of those cases, so they shelved development of the drug. Dr. Fisher bought the rights to the drug for $2 million, and then sold it to Tesaro for $121 million plus royalties, a huge profit over the $2 million we paid. Also, Tesaro believes that they can get the drug to work, and if so, in the future we will be getting royalty payments, which Tesaro says will be double digit, meaning 10% or higher.
The Pfizer human growth hormone deal gave us a large cash balance, enough to allow us to develop our other drugs, even with our high cash burn. That was why our stock was climbing. And the new maneuver by Dr. Frost, acquiring BRLI for shares instead of cash, puts us in an even better position.
BRLI has a large library of genetic data plus it has proprietary sequencing technologies that will greatly enhance Opko Health's development of drugs. BRLI also has a large sales force, here in America, and also Europe, with connections to insurance companies and doctors, and this will facilitate the ramp up the sales of OPK's prostate 4Kscore blood test, plus their large sales force can be used to sell our other drugs as they are approved.
Combining the two companies will also drastically increase OPK's money flow. BRLI's annual revenue was 832 million dollars last year, almost ten times OPK's revenue of 91 million dollars, plus BRLI had a profit of 47 million dollars, which is growing yearly, and will certainly help us out. Just with this acquisition, we have become a much stronger overall company.
Dr, Fisher keeps acquiring companies that complement our corporation and so make us stronger. On 5 May 20125 we acquired the private Irish company, EirGen Pharma which manufactures high potency drugs such as those used for cancer chemotherapy which are unsuitable for manufacture in normal multi-product facilities due to cross contamination risks. So we will be able to manufacture our drugs in their facilities. They are also a profitable company, and that will add more money to our cash flow.
Over time we will acquire more companies that complement our corporation, including companies that are working on new breakthrough medications, and these will add to our growing portfolio of world class medications. All of this means that we will continue growing and so will our stock price.
Some people might worry that since we have over half a billion shares of stock, that it will be difficult for our stock price to rise, so I compared our company with another pharmacology company with over half a billion shares, way over half a billion shares.
Johnson and Johnson, JNJ, a large health care company, has 2.8 billion shares, which is 5.2 times the number of shares that we will have with our combined companies. JNJ made a profit of 52.2 billion dollars last year, and since it has 5.2 times as many shares as we have, that would be the equivalent of us making a profit of 10 billion dollars: $52.2/5.2 = $10.04 We aren't to the point of making 10 billion dollars in profit at this time, in fact we are losing money, but we have a cash balance of $623 million which will allow us to fund our drug tests through FDA approval. When you add up all of the potential revenue we will be getting if all our drugs are approved, eventually we will be getting much more than $10 billion in profits. All our drugs added up, just using the conservative estimates, comes to $30 billion, and since the profit on drugs that are not facing competition is 50%, that comes to $15 billion in profits. JNJ's stock price has been steady around $100/share. So on an equivalent basis, we could reach $100/share, or higher, if we earn profits of over $10 billion a year when all our drugs are approved. Especially since we will probably have more drugs in the pipeline as time goes by.
Another thing to consider. JNJ has a dividend of $3 per share. In the future, when OPK is established and has a steady cash flow, there is a good chance that it will also start paying dividends, and when it does, in a few years of dividend payments, you would make back more money in dividends than you had paid for the stock.
today annual share holder meeting presentations
http://files.shareholder.com/downloads/OPKO/1575472x0xS1193125-15-227488/944809/filing.pdf
post from another message board
stargazer123 Thursday, 06/18/15 01:01:02 AM
Re: None
Post # of 3850
Some financial commentators have said that OPK's stock price dropped because the shares that they will be issuing to the BRLI stockholders will increase the number of shares of OPK so much that it will dilute the value of the stock, but none of the commentators reported the percentage of dilution.
Opko Health will issue 2.75 shares of OPK for each share of BRLI. BRLI has 27.85 million shares, so OPK will issue 76.6 million new shares.
OPK has 458.4 million shares, which means that the share count will increase 16.7% to 535 million shares. So the dilution factor is 16.7%
Just before the announcement that OPK would be acquiring BRLI by issuing shares, OPK's stock price was $19.12 Using a dilution factor of 16.7% would mean that the stock should have dropped from $19.12 to $15.91, but it has dropped below that, and of course, it could drop further. However, prior to the BRLI acquisition announcement, OPK was in a strong uptrend. From mid 2013 until December 2014, a period of over a year, the stock stayed in the $8 range. Then in December it started climbing at a steep angle and reached and stabilized at $14 for three months. In May it shot up to $18, which it stayed at for two weeks, and then spiked to $19. And that was when OPK made the announcement about BRLI, and the stock took a nose dive.
But there were good reasons why we had been in a strong uptrend, and why we will resume it.
Not too long ago commentators were saying that Opko Health was a dangerous stock to be in and rated it a sell, because it was burning cash faster than it was generating it. The number of short sellers was also increasing. OPK's revenues have been growing over time. In 2011 they were 28 million dollars, 2012 47 million dollars and by 2014 they were 91 million dollars. But expenses have also been growing, because running the many drug study tests is expensive, and so OPK has never made a profit.
But then Dr. Fisher turned things around. Something for which he is famous. He knew that one of the drugs we were working on, a long acting human growth hormone (hGH), was a drug that Pfizer would be interested in. Pfizer had been waiting for the drug to enter a phase III test level, because that would mean that it had passed most of the FDA requirements and would most likely get approved.
hGH is given to children 2 years and older that have not reached the minimum normal height range. And increasingly, doctors are also prescribing it for adults. It increases muscle mass in the elderly. It also increases muscle mass in cancer and AIDS patients that have developed cachexia, a condition where the body breaks down muscle mass. In addition to that, hGH increases heart function, stamina, sexual ability in men and reverses vaginal dryness and fragile/thin vaginal skin in older women. It also enhances the immune system. Because of these reasons, and many more, it is being increasingly prescribed for adults. And as the population ages, hGH sales will be in a strong uptrend.
The problem is that all human growth hormone drugs in current use have to be injected daily. That makes many people decide against using it, plus daily injections are expensive. OPK has developed a long acting hGH that only has to be injected once a week. It is in phase III in adults and phase II in children. The present yearly market for hGH drugs is 3 billion dollars a year. Since our drug only needs to be given once a week, instead of daily, it will be the drug of choice. Plus more people will decide to take it since it only needs to be taken once a week, and more people will choose to take it because it will also be less expensive since it is not used every day.
But even though this was a drug that would be an excellent cash cow if the drug trials could be advanced all the way through FDA approval, we didn't have enough money to finish running the tests on hGH, plus all our other drugs. Dr. Fisher talked to Pfizer, and they came to the rescue. They gave us $295 million up front, which brought us to a cash balance of $348 million, plus they agreed to pay another $275 million dollars to fund both our child and adult studies through to FDA approval. And once Pfizer starts selling the drugs we will get royalty payments.
According to a paper on drug royalties, written by Goldscheider, since the company that develops the drug shoulders most of the expenses, they get a large royalty. And if it is a drug that will not face competition, and thus will be able to be sold for good profits, such as our drug, they will get even larger royalties. The company that acquires the rights to the drug and then starts selling the drug, after expenses, will usually have a profit of 50%. Per Goldscheider, royalties will be 25% of the profit for drugs not facing completion. That would work out to a 12.5% royalty and on revenues of $3 billion yearly, that would mean that OPK would get $375 million a year.
Dr. Fisher previously did a sleight of hand on another drug of ours. In 2009, Schering-Plough, a large pharmacological company, was working on the drug rolapitant for nausea and vomiting caused by chemotherapy. They hoped that it would be better than present drugs and longer acting, but their phase II trial didn't show that it was effective for either of those cases, so they shelved development of the drug. Dr. Fisher bought the rights to the drug for $2 million, and then sold it to Tesaro for $121 million plus royalties, a huge profit over the $2 million we paid. Also, Tesaro believes that they can get the drug to work, and if so, in the future we will be getting royalty payments, which Tesaro says will be double digit, meaning 10% or higher.
The Pfizer human growth hormone deal gave us a large cash balance, enough to allow us to develop our other drugs, even with our high cash burn. That was why our stock was climbing. And the new maneuver by Dr. Frost, acquiring BRLI for shares instead of cash, puts us in an even better position. (I will give a site later on that discusses the probability of the deal going through.)
BRLI has a large library of genetic data plus it has proprietary sequencing technologies that will greatly enhance Opko Health's development of drugs. BRLI also has a large sales force, here in America, and also Europe, with connections to insurance companies and doctors, and this will facilitate the ramp up the sales of OPK's prostate 4Kscore blood test, plus their large sales force can be used to sell our other drugs as they are approved.
Combining the two companies will also drastically increase OPK's money flow. BRLI's annual revenue was 832 million dollars last year, almost ten times OPK's revenue of 91 million dollars, plus BRLI had a profit of 47 million dollars, which is growing yearly, and will certainly help us out. Just with this acquisition, we have become a much stronger overall company.
This will give us the time to become a cash cow on our own.
Our 4Kscore test will soon be generating significant profits. Our prostate 4Kscore test has already been approved and OPK is contacting urologists and explaining that its use will greatly decrease the number of prostate biopsies that have to be performed. The test is being accepted by more and more urologists here in America, Europe and now Mexico. In fact, in just the last quarter, the number of urologists that said that they were going to use the test, increased by 50%.
Every procedure done by a doctor has a CPT (Current Procedural Terminology) code number assigned to the procedure, and it is that number that is sent to the insurance company and Medicare for payment. Without that code, the patient has to pay for the test themselves, and so actual use of the test has been low. We have finally been issued our CPT code, and now use of our 4Kscore test should dramatically increase. According to what I have found in researching the 4Kscore test, the yearly income should eventually be 2 billion dollars, and then climbing, because the number of men being diagnosed with prostate cancer is growing yearly.
We have a number of drugs we are developing which will also be significant cash generators.
We are in the final stages of getting approval for Rayaldee, the first and only modified slow release formula of calcifediol, a major transport form of vitamin D, for end stage renal disease patients. In patients with end stage renal disease, when they take vitamin D, the body produces an abnormal enzyme CYP24, which destroys it. Even taking very high doses of vitamin D will not overcome this destructive process. This causes patients with kidney disease to have extremely low levels of vitamin D which causes the bones to lose calcium into the blood stream. The calcium is then deposited into the soft tissues, such as the veins, and causes severe cardiovascular disease and other problems. Rayaldee is a first in class slow released vitamin D drug and the Phase I and II tests have shown that it does not cause the release of CYP24, and in addition to that, it raised the vitamin D levels to normal levels.
Dr. John Cannell, an acknowledged expert on calcifediol, was so impressed with our Rayaldee drug that on 6 January 2014 he wrote that he had invested his life savings in OPK. OPK stock at that time was in the $8 to $9 range, so even at $15 a share he is in good shape.
Opko Health, in its press release, said that sales of Rayaldee should reach $6 billion a year. This may sound like a lot, but analyst reports that I have read, put the amount at $12 billion to $24 billion dollars a year if it is used world wide and $6 billion just for the U.S. market. And since the company plans on selling it in Europe, Mexico + Central America, and Asia, I would think that sales of $6 billion a year is conservative. In fact, OPK, in its legal Form 8K filing, lists it as worth $12 billion a year.
OPKO owns global rights to a heparin-derived oligosaccharide intended for therapeutic use in asthma and COPD (chronic obstructive pulmonary disease) as well as cystic fibrosis and other respiratory diseases. It is more efficient than current asthma medications and doesn't have their side effects.
Initial studies, using animals, have demonstrated successful anti-inflammatory and anti-allergic activity when administered orally or inhaled with inhalers or nebulizers. Human feasibility studies for asthma have also proven successful.
OPK also has an advanced inhaler which is superior to present inhalers and easier to use.
Inspiromatic™ offers improved drug deposition to the lower airways of patients and real time data for patient compliance monitoring. The device has an internal microcontroller and flow sensor that controls the delivery of the medication and, using micro-pump technology, dispenses the drug particles at the right speed without the need for forceful inhalation. It also provides instant feedback to the patient with a green or red flasher light to indicate proper inhalation and a beeper after the dose has been delivered. For physicians, Inspiromatic™ provides a built-in logger that stores patient use data for easy access and transmission by electronic devices such as smart phones.
In a recently completed, First In Man double blind clinical study, conducted with 30 asthmatic children, comparing Inspiromatic™ to a market leading inhaler, it demonstrated superior pulmonary delivery of the active drug.
The present drug of choice is Advair, which also uses an inhaler. Its annual sales are +$2 billion a year. OPK's drug is more effective and has less side effects, plus its inhaler is much more effective, so it will probably win over much of the market and should end up with sales in the range of $2 billion.
OPK’s Factor VIIa hemophilia drug is unlike any of the hemophilia drugs now in use. It has received an orphan drug designation, so that means it will be fast tracked to approval. All the hemophilia drugs in use today have to be given by IV and are short acting, only staying active in the body for about a day. Bayer, and two other companies, are developing a longer acting drug that only has to be given once a week, but those drugs also have to be given by Intravenous Injection. This is especially difficult for infants and children because they have such tiny veins, but it is also awkward and painful for adults. Either a needle has to be inserted into their vein, which is painful and causes scaring of the vein, which over time makes the vein unusable, or a port has to be inserted, and long term IV ports have a risk factor of becoming infected.
OPK has developed a long acting drug, which also only has to be given once a week, but it is given subcutaneously. Subcutaneously means under the skin. The medicine is drawn up into a syringe and then injected under the skin using a tiny needle. You don't use a long or big needle because the medication is given into the layer of fat under the skin in the abdomen. The fatty tissue is filled with tiny capillaries which slowly absorb the medication. A larger needle, like the ones given for shots in the buns, ouch, are not used, you don't want the needle to go through the layer of fat and into the muscle, because the muscle is filled with blood vessels, plus there is a lot of movement of the muscle, and so the medicine would be absorbed much faster and so last a shorter time. For the same reason, the medicine isn't injected into the fat layer of the arm or leg, because the movements of the arm and leg would increase its absorption and its coagulation activity would stop working in less than a week..
People can do the procedure by them selves at home. Or parents can do it for their children. The drug can be used for emergency episodes, such as a cut, but its main use would be self-administration at home for prophylactic use to prevent bleeding episodes. Hemophiliacs can spontaneously start bleeding for no apparent reason, typically into the joints and muscles, and that can cause permanent damage over time. Therefore it would be best to be given on a regular (weekly) basis for life. That is why it would bring in so much money for our company, because it will be given for life and not just for occasional emergency uses. Since our medication is given subcutaneously, instead of by IV, it would be the drug of choice. OPK states it would be worth $3.5 billion a year.
OPK, working with The Scripps Research Institute, is developing the only Parkinson drug that can actually stop the progression of the disease, instead of just delay it. SR 3306, a novel compound discovered by scientists at The Scripps Research Institute, stops the death of the brains cells whose destruction leads to Parkinson's disease. In the mid brain area is a group of dark colored cells, called substantia nigra, which produce a compound called dopamine. The dopamine is transported along the axons of the nigra cells to the stratium cells that control the movement of the muscles.
In Parkinson's disease, the substantia nigra cells die off and as the stratuin muscle controlling cells receive less dopamine, a person loses control of his muscles. Dopamine will not cross the blood brain barrier, bit it turns out that levodopa, a compound produced by certain plants, will travel through the blood stream, cross the blood brain barrier, and enter the brain. Once levodopa has entered the central nervous system, it is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase. Levodopa's effect on Parkinson's disease isn't a new discovery, over 7,000 years ago, in 5,000 BC, there are recordings of people with symptoms identical to Parkinson's and they were treated with the plants that contain levodopa. The extra dopamine that is produced by the levodopa, along with the output of dopamine from the remaining nigra cells, gives a person back normal control of their muscles. The problem is, that the nigra cells continue to die off, and increasing the levodopa to compensate for their loss can't be done because large amounts of levodopa are toxic. Because the nigra cells continue to die off, eventually their production of dopamine isn't enough to maintain muscle control and the person starts a downward spiral to death.
OPK's SR 3306 compound inhibits a class of enzymes called jun-N-terminal kinases (JNK) that are involved in the death of substantia nigra cells in persons with Parkinson's disease.
JNK is involved in apoptosis (self induced cell death) and survival signaling of cells and was identified in the death of neuronal cells. Since people with Parkinson's already have decreased nigra cells, and so don't produce enough dopamine, they will still need to continue taking their levodopa, but they will also be given SR 3306, which will stop the destruction of their remaining nigra cells, and so it will stop the actual progression of the persons Parkinson's disease. This is a life changing event. Something that no other drug can do, and in situations where there is no known drug to stop a disease, the FDA has a special fast tract procedure that they use. Our drug fits in this category.
There are over a million people with Parkinson's disease in America and another 9 million worldwide. The market for our Parkinson's drug would be over a billion dollars a year.
Here is a drug that could be interesting. OPK is working on a new vaccine design that could be applied to vaccines for regular influenza, plus the many strains of influenza such as ‘swine flu’, ‘bird flu’, and perhaps other viral diseases such as Hepatitis C and HIV.
Hemagglutinin is the key molecule that determines the entry of a virus into a host cell. Experiments were done to see how the hemagglutinin protein found on the surface of influenza viruses binds to the host cell, including how glycans (sugar chains) attached to the surface of hemagglutinin affect the binding. The surprising discovery was made that hemagglutinin stripped of most of its glycans bound more strongly to host molecules than fully glycosylated hemagglutinin. Vaccines were constructed and tested on mice. The investigators found that the ‘nearly naked’ mono-glycosylated hemagglutinins were able to neutralize a broader spectrum of virus types than the regular fully glycosylated hemagglutinins. They also found that mice given a vaccine made from hemagglutinins with less glycan attached to the surface and then given a lethal dose of influenza virus, increased survival rate by up to 50% in comparison with unvaccinated animals.
Up until now, only regular fully glycosylated hemagglutinins have been used in the production of vaccines. The mono-glycosylated hemagglutinin as a vaccine in this study showed a stronger immune response with broader neutralizing activities against H5N1 and H1N1 influenza. Dr. Che Ma, one of the investigators in the mouse study, said, "It might be a better strategy to design vaccines with hemaglutinins stripped of glycans.” The team leader, Dr. Chi-Huey Wong said,”Glycan modeling and the concept of consensus protein sequence in the design are the two keys which pave the way to the development of a universal vaccine against influenza and other human viruses.“ A universal virus vaccine would be a game changer.
Opko Health has been trying to develop a vaccine using this technique for five years, but so far has not come up with a vaccine that meets the criteria for a phase I test. If we ever come up with a vaccine that works, that could be a real money maker.
And finally, all the reports that I have read say that our calcifediol end stage kidney disease medication will be our biggest winner at $12 billion a year, while they only mention in passing the drug that I think could be our biggest money maker, literally worth tens of billions of dollars a year. In Opko Healths Form 8K filing it stated that the drug would bring in over 15 billion dollars a year. That drug is our weight reducing candidate, and what is interesting, is that it also directly lowers blood sugar levels and cholesterol levels.
Because obesity isn’t a disease, regulators have a low tolerance for worrisome side effects. On the other hand people that are morbidly over weight (and are designated as obese, not just overweight) develop many medical problems, such as diabetes, and die young. Weight loss counseling and the weight loss medications available today do not work on these people. 400,000 people in America die from obesity related problems every year. So far the only treatment available is a gastric bypass surgery called Roux-en-Y, which itself can cause life threatening complications. So if a medication was developed that induced weight loss in this group of people, and thus obviate the need for surgery, the FDA would consider expediting its approval, especially considering the death toll from obesity related problems.
Drug companies have spent decades and over a billion dollars trying to come up with a weight loss drug. Older weight loss medicines made by companies like Sanofi and GlaxoSmithKline Plc stumbled because they were deemed too dangerous or came with unpleasant side effects. In the last few years four new drugs have been approved by the FDA, but so far their sales have been weak.
OPK, along with Prolor Biotech, are working on oxyntomodulin, a peptide hormone produced by cells in the small intestine where It is released into the bloodstream when a person ingests food and travels to the brain, where it acts to enhance satiety and reduce appetite. Since it is a natural compound produced by the body, previous tests showed that it did not have any side effects. Previous companies have tested it, and it did induce weight loss, but it is short acting and had to be injected subcutaneously multiple times a day, usually just before meals. Which was awkward. How would you like to inject yourself just before you eat at a restaurant? Or even before meals at home or at work.
Other companies tried to make a long acting form of oxyntomodulin, but all the forms that they came up with had only weak weight loss effects. When they changed the structure of the oxyntomodulin molecule, it lost its effectiveness. However, Dr. Frost is famous for either taking previous medications that were ineffective and redesigning them to greatly enhance their properties, or finding and buying companies that had come up with a redesigned medication. He has done it again with oxyntomodulin.
Prolor Biotech, using Reversible PEGylaton technology, which leaves a compound intact, but adds a molecular tail to it to change its characteristics, has developed a long acting oxyntomodulin (dual GLP-1/Glucagon agonist) called MOD-6030. It is a slow release form of the intact oxyntomodulin, enabling a prolonged exposure of the peptide while maintaining its biological activity and the ability of the peptide to pass the blood brain barrier. Tests showed that it only has to be given once a week. Unexpectedly, not only did the drug not lose any of its effectiveness, it had a much stronger weight loss effect than the natural hormone oxytomodulin itself, and it even improved glycemic control, lowering blood sugar levels, thus meaning it could also be used as a diabetic drug, plus it had a large cholesterol lowering effect. It should be noted that diabetics also have problems with elevated cholesterol. It turns out, that since it stays active in the body for days at a time instead of just a few hours, its effects are strongly enhanced and factors that weren't previously apparent, such as its diabetic and cholesterol properties, show up.
In a 30 day animal study, animals in the placebo group showed minimal changes in the study parameters, while the animals receiving MOD-6030 achieved on average a 28% reduction in weight, a 29% reduction in food intake, a 19% reduction in blood glucose levels and a 57% reduction in cholesterol levels. The lead investigator stated, “We believe there is great demand among obese patients and their physicians for therapies that will help patients lose weight and reduce elevated glucose levels." I would add that diabetic doctors would also be interested in the drug, either as a stand alone drug, or for it to be given along with a patients diabetic drugs. And since diabetic drugs have side effects, some of them serious, adding our drug to their protocol may enable them to lower the dosage of their diabetic drug, thereby decreasing their risk of side effects.
As of January 2015, over 2 billion adults, 18 years or older worldwide, were overweight, and of those, over 600 million were obese. In America over 70 million adults are obese. Because of this, OPK states that its weight loss medication could bring in $15 billion a year. Other analysts put the number even higher. What none of them mentioned was that there are over 400 million diabetics world wide, with 70 million being in America. I would think that a number of those could end up taking our drug, so we could end up making well over 15 billion dollars a year if our weight loss drug works. Even if we only end up with a lower percentage of that, it would still be a very lucrative drug.
Some people might worry that since we have half a billion shares of stock, that it will be difficult for our stock price to rise, so I compared our company with another pharmacology company with over half a billion shares, way over half a billion shares.
Johnson and Johnson, JNJ, a large health care company, has 2.8 billion shares, which is 5.2 times the number of shares that we will have with our combined companies. JNJ made a profit of 52.2 billion dollars last year, and since it has 5.2 times as many shares as we have, that would be the equivalent of us making a profit of 10 billion dollars. ($52.2/5.2 = 10.04%) We aren't to the point of making 10 billion dollars in profit at this time, in fact we are losing money, but if you add up all of the potential revenue we will be getting if all our drugs are approved, eventually we will be getting much more than $10 billion in profits. All our drugs added up, just using the conservative estimates, comes to $30 billion, and since the profit on drugs that are not facing competition is 50%, that comes to $15 billion in profits. JNJ's stock price has been steady around $100/share. So on an equivalent basis, we could reach $100/share, or higher, if we earn profits of over $10 billion a year when all our drugs are approved. Especially since we will probably have more drugs in the pipeline as time goes by.
Another thing to consider. JNJ has a dividend of $3 per share. In the future, when OPK is established and has a steady cash flow, there is a good chance that it will also start paying dividends, and when it does, in a few years of dividend payments, you would make back more money in dividends than you had paid for the stock.
People have pointed out that BRLI stockholders have to approve the transaction of OPK acquiring BRLI. BRLI has been stuck in the $30 range since 2012. OPK has been climbing during that time. The two companies combined would be an especially strong entity, so it would also tend to climb in price, probably even more strongly than OPK by itself has been climbing. From what I have been able to find out, 80% of BRLI stock is held by institutions. They know that Dr. Frost is in charge of OPK, and they are aware that he is brilliant in turning companies into money making machines. I think that they will be thrilled that BRLI is going to become part of OPK.
Here is a write up by an analyst that covers BRLI. He concludes that maybe the transaction will be approved or maybe it won't, but leans towards maybe it will.
http://seekingalpha.com/article/3243826-bio-reference-laboratories-a-conundrum-wrapped-in-an-enigma
For matters of disclosure, since people might accuse me of pumping OPK stock, I will say that I have accumulated 3,000 shares of OPK at an average price of $15.67, which cost me $47,000. Like Dr. John Cannell, this is most of my life's savings. I bought the stock because I think that it is a great buy. And obviously, so does Dr. Frost and many of our other insiders because they have been steady in buying our stock. Of course, they could be wrong, but they know a lot more of what is going on with our stock than I do. They know its financial shape and how the drug tests are going, and they are very enthusiastic in their buying. They must have talked to the BRLI management prior to arranging for OPK to acquire it, and they may have even talked to some of the institutions that own BRLI stock. And they are still buying OPK stock. That speaks volumes!
Some of the write ups that I have read, say that since we have such a large cash burn rate, if the merger isn't approved, and we don't end up with BRLI's cash flow and profits, our stock will crash and maybe even go bankrupt. Not one of them have mentioned that even without BRLI, we have a cash balance of 348 million dollars, enough to fund all our studies, even with our cash burn. So we don't have to worry about bankruptcy. Also, Pfizer will be paying us another 275 million dollars, and that will give us a cash balance of 623 million dollars (minus the money spent to fund our studies and other corporate expenses). So we have over half a billion dollars to fund our company, and even if the merger of the two companies isn't approved, we will still do great. Great if the merger goes through, great if it doesn't. That is what you call a win-win situation.
Good luck every one
SVON: FROST STOCK WITH BIGGEST UPSIDE POTENTIAL
With a market cap of only $15 million, SVON has the potential for a huge upside move.
Remember, Frost and OPK own at over $2.00/share and just invested more.
This one is ready to explode IMHO
KAE
SVON will get lots of eye on Weekend.13m cap. ATMN trading 100m+
June 16, 2015 will be interesting and prob. the upcoming Conference Call
Sevion Therapeutics to Present at 2015 BIO International Convention« back
SAN DIEGO, CA – June 3, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Miguel de los Rios, Ph.D., Vice President of Research and Development, will present an overview of the Company’s technology and programs at the 2015 BIO International Convention in Philadelphia, PA on June 16, 2015. “We are excited to share our discoveries and progress with the biotechnology community at BIO 2015, particularly our progress in identifying and developing antibodies against high-value difficult targets like ion channels and GPCRs,” noted Dr. de los Rios. The Company employs unique strategies to discover antibodies against multipass membrane proteins, including utilization of a novel cow antibody scaffold which was featured on the cover of Cell in 2013.
About Sevion Therapeutics
Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com.
ATNM, Frost just invested and bought shares at 2.60! New play to add to the portfolio.
http://www.smarteranalyst.com/2015/06/04/stock-update-nysemktatnm-actinium-pharmaceuticals-inc-announces-5-million-registered-direct-offering-of-common-stock/
SVON nice products,SNS01-T (oncology)-Clinical!, http://www.seviontherapeutics.com/pipeline/
he needs to get some PKTX to imo.
$OPK - OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger
8:00 AM ET 6/8/15 | BusinessWire
OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference Laboratories' second quarter financial results. This joint call will be in lieu of the separate earnings call previously announced by Bio-Reference Laboratories.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150608005669/en/
The conference call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. A link to the live webcast is also included below.
CONFERENCE CALL & WEBCAST INFORMATION:
WHEN: Thursday, June 11, 2015, 8:30 a.m. ET
DOMESTIC & CANADA DIAL-IN: 1-877-407-0789
INTERNATIONAL DIAL-IN: 1-201-689-8562
LIVE WEBCAST LINK: http://public.viavid.com/index.php?id=114915
For those unable to participate in the conference call or webcast, a replay will be available beginning June 11, 2015 at 5 p.m. ET for a period of time. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay passcode is 13611685.
The replay can also be accessed for a period of time on OPKO's website at www.opko.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
About Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories, Inc. is one of the largest and fastest growing full service diagnostic laboratories in the world, providing clinical testing services to physician offices, clinics, hospitals, long- term care facilities and employers while also advancing drug discovery and development with disease foundations, academic and pharmaceutical partners. Bio-Reference Laboratories' comprehensive testing capabilities and expertise spans molecular diagnostics, anatomical pathology, women's health, oncology and rare disease genetics. Bio-Reference Laboratories, and its subsidiaries, has an international presence in more than 50 countries. For more information, visit www.bioreference.com.
Important Information For Investors And Shareholders
This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Bio-Reference Laboratories, Inc. ("Bio-Reference Laboratories") and OPKO Health, Inc. ("OPKO"). In connection with this proposed business combination, Bio-Reference Laboratories and/or OPKO will file relevant materials with the Securities Exchange Commission (the "SEC"), including an OPKO registration statement on Form S-4 that will include a proxy statement of Bio-Reference Laboratories and constitute a prospectus of OPKO. INVESTORS AND SECURITY HOLDERS OF BIO-REFERENCE LABORATORIES AND OPKO ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Any definitive proxy statement (if and when available) will be mailed to shareholders of Bio-Reference Laboratories. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by Bio-Reference Laboratories and/or OPKO through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Bio-Reference Laboratories will be available free of charge on Bio-Reference Laboratories' website at http://www.bioreference.com or by contacting Bio-Reference Laboratories' Investor Relations Department by email at tmackay@bioreference.com or by phone at (201) 791-2600. Copies of the documents filed with the SEC by OPKO will be available free of charge on OPKO's website at www.opko.com or by contacting OPKO's Investor Relations Department by email at contact@opko.com or by phone at (305) 575-4100.
Participants in Solicitation
Bio-Reference Laboratories, OPKO, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Bio-Reference Laboratories is set forth in its Annual Report on Form 10-K for the year ended October 31, 2014, which was filed with the SEC on January 13, 2015, its Quarterly Report on Form 10-Q for the quarter ended January 31, 2015 which was filed with the SEC on March 9, 2015 and its Current Reports on Form 8-K, which were filed with the SEC on March 5, 2015, and April 29, 2015. Information about the directors and executive officers of OPKO is set forth in its amended Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 27, 2015 and April 30, 2015, its proxy statement for its 2015 annual meeting of stockholders, which was filed with the SEC on May 7, 2015, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 which was filed with the SEC on May 11, 2015 and its Current Report on Form 8-K, which was filed with the SEC on March 19, 2015.
These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this communication regarding the proposed acquisition of Bio-Reference Laboratories by OPKO, including any statements regarding the expected timetable for completing the proposed transaction, synergies, benefits and opportunities of the proposed transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding OPKO's and Bio-Reference Laboratories' future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are "forward-looking" statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "anticipate," "believe," "ensure," "expect," "if," "intend," "estimate," "probable," "project," "forecasts," "predict," "outlook," "aim," "will," "could," "should," "would," "potential," "may," "might," "anticipate," "likely" "plan," "positioned," "strategy," and similar expressions, and the negative thereof, are intended to identify forward-looking statements.
All forward-looking information are subject to numerous risks and uncertainties, many of which are beyond the control of Bio-Reference Laboratories and OPKO, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: failure to obtain the required vote of Bio-Reference Laboratories' shareholders; the timing to consummate the proposed transaction; the risk that a condition to closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction might otherwise not occur; the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; the diversion of management time on transaction-related issues; ability to successfully integrate the businesses; risk that the transaction and its announcement could have an adverse effect on Bio-Reference Laboratories' ability to retain customers and retain and hire key personnel; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; new information arising out of clinical trial results; and the risk that the safety and/or efficacy results of existing clinical trials will not support continued clinical development, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. OPKO and Bio-Reference Laboratories do not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Bio-Reference Laboratories' and OPKO's respective filings with the SEC and available through the SEC's Electronic Data Gathering and Analysis Retrieval system at www.sec.gov, including Bio-Reference Laboratories' and OPKO's most recent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Bio-Reference Laboratories and OPKO assume no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150608005669r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20150608005669/en/
SOURCE: OPKO Health, Inc.
OPKO CONTACT:
Steve Rubin or Adam Logal
305-575-4100
or
BRLI CONTACT:
Richard L. Faherty, 201-791-2600
TPIV .75 +19%, can't wait the other one mentioned here...
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
416
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators starbuxsux |
Dr. Frost's brilliance
Dr. Frost was chairman at Mt. Sinai Medical Center in Florida and a consultant at Miles Laboratories when he met the manager, Michael Jaharis. They learned of a pharmaceutical company that had just lost $700,000 and couldn't afford to bring out a new drug.
Dr. Frost figured they could customize a new delivery system to effectively speed past the typical decade-plus drug commercialization route involving tens of millions of dollars. He invested $50,000 in the company, Key Pharmaceuticals, and found a new way of delivering an existing drug into the body.
Next, Dr. Frost and Mr. Jaharis took on a crotchety asthma medication. Theophylline was a little-used older drug, ineffective in small doses but toxic in large doses. So, Key researchers devised a way to incorporate the drug into a 12-hour time-release pill.
Blessed with good luck and good leadership, Key continued its unique pathway. The company didn't have the roughly $30,000 needed to test the pill but The University of Florida agreed to test it and publish the results. Rather than spending a lot of money on marketing, Key offered allergists pill samples backed by scientific data and a calculator to figure accurate dosage.
With successful drugs marketed, agreements with larger pharmaceutical companies followed. The realization hit the partners in 1986: They had, indeed, found the key to building a $50,000 straggler into a behemoth. They sold Key Pharmaceuticals to Schering-Plough for $800 million.
In 1987, Dr. Frost jiggled the key to open up the potential of generic products company Ivax. The company became the world's largest maker of low-priced copies of brand drugs whose patents had expired. The business was tough and disheartening at times - like the time a lucrative Norwegian merger fell apart in 1995. But Dr. Frost shoved away that disappointment.
He sold the business in 2005 to Teva Pharmaceutical Industries for a cool $7.6 billion.
The doctor from Miami Beach, Fla. continued his magic as he began building Opko Health in 2007. Today, the pharmaceutical and diagnostic company boasts a $4 billion market cap and a respected chief executive.
"Every company we've built has always had skeptics," he said. "And they have always paid the price in the end."
Dr. Frost indicated OPK is targeting multiple medical markets worth about $30 billion. We wouldn't be surprised if, at some point, Dr. Frost's company becomes an acquisition target of a large pharmaceutical company searching for promising drugs to replace its drugs with expiring patents.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |